Back on the public stage, SciClone is open for business

After returning to the public markets at 3x its 2017 go-private value, China-focused in-licensing play SciClone is planning to be “much more aggressive” in its dealmaking, with its sights set on eventually taking Chinese products to the West.

Listed on NASDAQ for more than two decades, SciClone Pharmaceuticals Inc. had positioned itself as the partner of choice for Western biopharma companies looking to get their drugs onto the China market. The experience of CEO Friedhelm Blobel, a longtime veteran of pharma MNCs who led SciClone for more than a decade, and the company’s U.S.-listing gave potential partners assurances about entering the rapidly developing market as well as matters of compliance with securities regulations...